Human Recombinant DGKE, Active protein, His Tag (V2LY-0526-LY3562)

Name: Human Recombinant DGKE, Active protein, His Tag
SKU: V2LY-0526-LY3562
Rating: 5 (1 reviews)

See all DGKE antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

Baculovirus-Insect Cells

Protein Species

Human

Tag

His Tag

Protein Construction

This product is Human Recombinant DGKE, Active protein, His Tag consist of Amino Acid: Full Length and predicts a molecular mass of 65 kDa.

Molecule Mass

65 kDa

Sequence

Amino Acid: Full Length

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

Batch dependent.

Endotoxin

Please contact us for more information.

Format

Liquid

Buffer

Tirs, NaCl, Glycerol

Preservative

None

Storage

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

More Infomation

Target

Full Name

diacylglycerol kinase, epsilon 64kDa

Function

Membrane-bound diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:15544348, PubMed:19744926, PubMed:22108654, PubMed:21477596, PubMed:23949095).

Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (PubMed:8626589, PubMed:15544348).

Also plays an important role in the biosynthesis of complex lipids (PubMed:8626589).

Displays specificity for diacylglycerol substrates with an arachidonoyl acyl chain at the sn-2 position, with the highest activity toward 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol the main diacylglycerol intermediate within the phosphatidylinositol turnover cycle (PubMed:19744926, PubMed:22108654, PubMed:23274426).

Can also phosphorylate diacylglycerol substrates with a linoleoyl acyl chain at the sn-2 position but much less efficiently (PubMed:22108654).

Biological Process

Diacylglycerol metabolic process Source: UniProtKB
Intracellular signal transduction Source: GO_Central
Lipid phosphorylation Source: UniProtKB
Modulation of chemical synaptic transmission Source: Ensembl
Phosphatidic acid biosynthetic process Source: UniProtKB
Phosphatidylinositol biosynthetic process Source: Ensembl
Platelet activation Source: Reactome
Protein kinase C-activating G protein-coupled receptor signaling pathway Source: InterPro

Cellular Location

Cytoplasm; Membrane

Involvement in disease

Nephrotic syndrome 7 (NPHS7):
A form of nephrotic syndrome, a renal disease clinically characterized by severe proteinuria, resulting in complications such as hypoalbuminemia, hyperlipidemia and edema. NPHS7 is an autosomal recessive form characterized by onset of proteinuria usually in the first decade of life. The disorder is progressive, and some patients develop end-stage renal disease within several years. Renal biopsy typically shows membranoproliferative glomerulonephritis.
Hemolytic uremic syndrome atypical 7 (AHUS7):
An atypical form of hemolytic uremic syndrome characterized by acute onset in the first year of life of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. After the acute episode, most patients develop chronic renal insufficiency. Unlike other genetic forms of aHUS, AHUS7 is not related to abnormal activation of the complement system.

Alabdulqader, M., & Alfakeeh, K. (2021). A patient with a homozygous diacylglycerol kinase epsilon (DGKE) gene mutation with atypical haemolytic uraemic syndrome and low C3 responded well to eculizumab: a case report. BMC nephrology, 22(1), 1-5.

Koyun, M., Aksoy, G. K., Çomak, E., Özaltın, F., & Akman, S. (2021). Outcome of diacylglycerol kinase epsilon–mediated hemolytic uremic syndrome in an infant. Kidney International, 99(6), 1500-1501.

Liu, D., Ding, Q., Dai, D. F., Padhy, B., Nayak, M. K., Li, C., ... & Attanasio, M. (2021). Loss of diacylglycerol kinase ε causes thrombotic microangiopathy by impairing endothelial VEGFA signaling. JCI insight, 6(9).

Fu, W., Li, M., Lin, H., Xu, Y., Han, W., Chen, H., & Sun, L. (2021). Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy. Clinica Chimica Acta, 518, 78-82.

Brocklebank, V., Kumar, G., Howie, A. J., Chandar, J., Milford, D. V., Craze, J., ... & Kavanagh, D. (2020). Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney international, 97(6), 1260-1274.

Holanda, M. I. D., Gomes, C. P., Araujo, S. D. A., Wanderley, D. C., Eick, R. G., Dantas, G. C., ... & Palma, L. M. P. (2019). Diacylglycerol kinase epsilon nephropathy: late diagnosis and therapeutic implications. Clinical kidney journal, 12(5), 641-644.

Sharma, A., Khandelwal, P., Yadav, M., Sethi, S., Hari, P., Sinha, A., & Bagga, A. (2019). Atypical hemolytic uremic syndrome with diacylglycerol kinase epsilon (DGKE) gene mutation. Asian Journal of Pediatric Nephrology, 2(2), 101.

So, V., Wu, J., Traynor-Kaplan, A., Choy, C., Epand, R., Botelho, R., & Lemaire, M. (2019). Phosphatidylinositol cycle disruption is central to atypical hemolytic-uremic syndrome caused by diacylglycerol kinase epsilon deficiency. bioRxiv, 633867.

Azukaitis, K., Simkova, E., Majid, M. A., Galiano, M., Benz, K., Amann, K., ... & Schaefer, F. (2017). The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase ε. Journal of the American Society of Nephrology, 28(10), 3066-3075.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant DGKE, Active protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Human Recombinant DGKE, Active protein, GST Tag (CAT#: V2LY-0526-LY3561)

Related Products

Mouse Anti-DGKE Recombinant Antibody (7E1) (CAT#: CBMAB-D0787-YC)

Mouse Anti-DGKE Recombinant Antibody (CBYCD-252) (CAT#: CBMAB-D0785-YC)

Mouse Anti-DGKE Recombinant Antibody (12K78) (CAT#: CBMAB-D0788-YC)

Mouse Anti-DGKE Recombinant Antibody (7E1) (CAT#: V2LY-0425-LY246)

Mouse Anti-DGKE Recombinant Antibody (12K78) (CAT#: V2LY-0425-LY247)

Human Recombinant DGKE, Active protein, GST Tag (CAT#: V2LY-0526-LY3561)

Mouse Anti-DGKE Recombinant Antibody (CBYCD-252) (CAT#: V2LY-0425-LY245)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry